Neurocrine Biosciences, Inc. Live Stock Price Today, Share Analysis and Chart

Name: Neurocrine Biosciences, Inc.: Is Infosys Ltd. worth buying?
Item: Neurocrine Biosciences, Inc.
Rating: 2.344861
Author: Trendlyne DVM scores

Turnaround Potential

about

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

133.99 -1.44 (-1.06%)

59.08% Gain from 52W Low

530.3K

XNAS Volume

XNAS 25 Aug, 2025 5:30 PM (EDT)

Medium Financial Strength

44.4 / 100

Mid Valuation

34.0 / 100

Technically Moderately Bullish

64.7 / 100

Turnaround Potential These stocks may be affordable or expensive due to their medium quality and a good technical scoring. However, their reasonable financials successfully attract investors. View Similar Embed DVM

168

1Yr Price target upside is 25%

26 analysts

Neurocrine Biosciences, Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Neurocrine Biosciences, Inc. Live Stock Price Today, Share Analysis and Chart

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

59.08% Gain from 52W Low

SWOT Analysis

Neurocrine Biosciences, Inc. Live Price Chart